

# Arnaud Petit

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1611274/publications.pdf>

Version: 2024-02-01

108  
papers

3,682  
citations

136950

32  
h-index

149698

56  
g-index

117  
all docs

117  
docs citations

117  
times ranked

6348  
citing authors

#	ARTICLE	IF	CITATIONS
1	A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. <i>Blood</i> , 2018, 131, 717-732.	1.4	240
2	Comprehensive mutational profiling of core binding factor acute myeloid leukemia. <i>Blood</i> , 2016, 127, 2451-2459.	1.4	198
3	High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. <i>Blood</i> , 2013, 121, 822-829.	1.4	189
4	International Retrospective Analysis of 73 Cases of Invasive Fusariosis Treated with Voriconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4446-4450.	3.2	158
5	Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. <i>Nature Genetics</i> , 2015, 47, 1334-1340.	21.4	152
6	Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2827-2832.	1.6	129
7	NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogénétique Hématologique. <i>Leukemia</i> , 2006, 20, 696-706.	7.2	120
8	Clinical Impact of <i>NOTCH1</i> and/or <i>FBXW7</i> Mutations, <i>FLASH</i> Deletion, and <i>TCR</i> Status in Pediatric T-Cell Lymphoblastic Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1966-1973.	1.6	111
9	Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. <i>Blood</i> , 2014, 124, 1445-1449.	1.4	105
10	Childhood Acute Leukemia, Early Common Infections, and Allergy: The ESCALE Study. <i>American Journal of Epidemiology</i> , 2010, 172, 1015-1027.	3.4	103
11	Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2018, 131, 289-300.	1.4	97
12	RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation. <i>Leukemia</i> , 2012, 26, 2384-2389.	7.2	91
13	Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. <i>Journal of Experimental Medicine</i> , 2012, 209, 2017-2031.	8.5	87
14	Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. <i>British Journal of Haematology</i> , 2016, 174, 887-898.	2.5	83
15	TLX Homeodomain Oncogenes Mediate T Cell Maturation Arrest in T-ALL via Interaction with ETS1 and Suppression of <i>TCR</i> Gene Expression. <i>Cancer Cell</i> , 2012, 21, 563-576.	16.8	81
16	Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. <i>European Journal of Cancer</i> , 2014, 50, 3206-3211.	2.8	79
17	NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis. <i>Leukemia</i> , 2017, 31, 565-572.	7.2	79
18	Genetic polymorphisms and childhood acute lymphoblastic leukemia: GWAS of the ESCALE study (SFCE). <i>Leukemia</i> , 2012, 26, 2561-2564.	7.2	68

#	ARTICLE	IF	CITATIONS
19	Loss of <i>RASGRP1</i> in humans impairs T cell expansion leading to Epstein-Barr virus susceptibility. <i>EMBO Molecular Medicine</i> , 2018, 10, 188-199.	6.9	61
20	ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia. <i>Cancer Cell</i> , 2017, 31, 452-465.	16.8	60
21	Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. <i>Blood</i> , 2018, 132, 187-196.	1.4	54
22	Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with <i>Clostridioides (Clostridium) difficile</i> Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE). <i>Clinical Infectious Diseases</i> , 2020, 71, 2581-2588.	5.8	50
23	Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol. <i>Haematologica</i> , 2012, 97, 1743-1750.	3.5	47
24	SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia. <i>Oncogene</i> , 2015, 34, 631-638.	5.9	47
25	CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. <i>Blood</i> , 2020, 136, 387-400.	1.4	46
26	The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 348-357.	7.2	44
27	The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. <i>Haematologica</i> , 2013, 98, 1711-1717.	3.5	41
28	Bone marrow sites differently imprint dormancy and chemoresistance to T-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2017, 1, 1760-1772.	5.2	41
29	Childhood acute lymphoblastic leukaemia and indicators of early immune stimulation: the Estelle study (SFCE). <i>British Journal of Cancer</i> , 2015, 112, 1017-1026.	6.4	40
30	Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group. <i>HemaSphere</i> , 2018, 2, e31.	2.7	40
31	Impact of early molecular response in children with chronic myeloid leukemia treated in the French Clivec phase 4 study. <i>Blood</i> , 2014, 124, 2408-2410.	1.4	37
32	Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia. <i>Cancer Discovery</i> , 2019, 9, 1736-1753.	9.4	37
33	NUP98-HMGB3: a novel oncogenic fusion. <i>Leukemia</i> , 2010, 24, 654-658.	7.2	33
34	Maternal reproductive history, fertility treatments and folic acid supplementation in the risk of childhood acute leukemia: the ESTELLE Study. <i>Cancer Causes and Control</i> , 2014, 25, 1283-1293.	1.8	33
35	Extensive molecular mapping of TCR $\alpha$ - and TCR $\beta$ -involved chromosomal translocations reveals distinct mechanisms of oncogene activation in T-ALL. <i>Blood</i> , 2012, 120, 3298-3309.	1.4	31
36	Early-onset granulomatous arthritis, uveitis and skin rash: characterization of skin involvement in Blau syndrome. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 340-348.	2.4	30

#	ARTICLE	IF	CITATIONS
37	Teledermatology for COVID-19 cutaneous lesions: substitute or supplement?. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e532-e533.	2.4	30
38	Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia. Leukemia, 2017, 31, 2594-2600.	7.2	28
39	An innovative pedagogic course combining video and simulation to teach medical students about pediatric cardiopulmonary arrest: a prospective controlled study. European Journal of Pediatrics, 2016, 175, 767-774.	2.7	25
40	In hematopoietic cells with a germline mutation of CBL, loss of heterozygosity is not a signature of juvenile myelo-monocytic leukemia. Leukemia, 2013, 27, 2404-2407.	7.2	23
41	Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Soci�t� Fran�saise de Greffe de Moelle et de Th�rapie Cellulaire. Bone Marrow Transplantation, 2014, 49, 382-388.	2.4	22
42	Google Glass for Residents Dealing With Pediatric Cardiopulmonary Arrest: A Randomized, Controlled, Simulation-Based Study. Pediatric Critical Care Medicine, 2017, 18, 120-127.	0.5	21
43	Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. Leukemia, 2022, 36, 1516-1524.	7.2	21
44	ARID5B, IKZF1 and Non-Genetic Factors in the Etiology of Childhood Acute Lymphoblastic Leukemia: The ESCALE Study. PLoS ONE, 2015, 10, e0121348.	2.5	20
45	TCR� rearrangements identify a subgroup of NKL-deregulated adult T-ALLs associated with favorable outcome. Leukemia, 2018, 32, 61-71.	7.2	20
46	Childhood diagnosis of genetic thrombocytopenia with mutation in the ankyrine repeat domain 26 gene. European Journal of Pediatrics, 2015, 174, 1399-1403.	2.7	19
47	Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21). Leukemia and Lymphoma, 2016, 57, 199-200.	1.3	19
48	Acute Myeloid Leukemia With Central Nervous System Involvement in Children: Experience From the French Protocol Analysis ELAM02. Journal of Pediatric Hematology/Oncology, 2018, 40, 43-47.	0.6	18
49	Maintenance Therapy With Interleukin-2 for Childhood AML. HemaSphere, 2018, 2, e159.	2.7	18
50	Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL. Leukemia, 2013, 27, 305-314.	7.2	16
51	Imatinib Is Efficient but Has a Negative Impact On Growth in Children with Previously Untreated chronic Myelogenous Leukaemia (CML) in Early Chronic Phase (CP): Results of the French National Phase IV Trial.. Blood, 2009, 114, 863-863.	1.4	16
52	Blueprint of human thymopoiesis reveals molecular mechanisms of stage-specific TCR enhancer activation. Journal of Experimental Medicine, 2020, 217, .	8.5	15
53	Functional analysis of young patients with desmoid-type fibromatosis: Initial surveillance does not jeopardize long term quality of life. European Journal of Surgical Oncology, 2020, 46, 1294-1300.	1.0	15
54	SNP-array lesions in core binding factor acute myeloid leukemia. Oncotarget, 2018, 9, 6478-6489.	1.8	15

#	ARTICLE	IF	CITATIONS
55	Functional analysis of the NUP98-CCDC28A fusion protein. <i>Haematologica</i> , 2012, 97, 379-387.	3.5	14
56	Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 425-427.	0.8	14
57	Hypoxia favors chemoresistance in T-ALL through an HIF1 $\alpha$ -mediated mTORC1 inhibition loop. <i>Blood Advances</i> , 2021, 5, 513-526.	5.2	14
58	Usefulness of $\beta$ -D-glucan for diagnosis and follow-up of invasive candidiasis in onco-haematological patients. <i>Journal of Infection</i> , 2018, 76, 483-488.	3.3	13
59	Infant cancers in France: Incidence and survival (2000-2014). <i>Cancer Epidemiology</i> , 2020, 65, 101697.	1.9	13
60	Contribution of HLA-A/B/C/DRB1/DQB1 Common Haplotypes to Donor Search Outcome in Unrelated Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1612-1618.	2.0	12
61	Appendicitis in a Neutropenic Patient: A Multicentric Retrospective Study. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, 365-369.	0.6	12
62	Parental smoking, maternal alcohol consumption during pregnancy and the risk of neuroblastoma in children. A pooled analysis of the ESCALE and ESTELLE French studies. <i>International Journal of Cancer</i> , 2019, 145, 2907-2916.	5.1	12
63	Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 1981-1988.	5.2	12
64	Infant Acute Myeloid Leukemia: A Unique Clinical and Biological Entity. <i>Cancers</i> , 2021, 13, 777.	3.7	11
65	Head and neck tumors in children and adolescents: Impact of a multidisciplinary tumor board. <i>Oral Oncology</i> , 2021, 114, 105145.	1.5	11
66	Rapid childhood T-ALL growth in xenograft models correlates with mature phenotype and NF- $\kappa$ B pathway activation but not with poor prognosis. <i>Leukemia</i> , 2015, 29, 977-980.	7.2	10
67	Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. <i>Journal of Hematology and Oncology</i> , 2021, 14, 74.	17.0	10
68	Frequency of relapse and persistent cutaneous symptoms after a first episode of chilblain-like lesion during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e566-e568.	2.4	10
69	Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins. <i>Blood Cancer Journal</i> , 2022, 12, 14.	6.2	10
70	Scopulariopsis brevicaulis abscess in a child treated for myeloblastic leukaemia. <i>Lancet Infectious Diseases</i> , 2011, 11, 416.	9.1	9
71	Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia. <i>American Journal of Hematology</i> , 2011, 86, 785-787.	4.1	9
72	French real-life experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia. <i>Experimental Hematology and Oncology</i> , 2012, 1, 39.	5.0	9

#	ARTICLE	IF	CITATIONS
73	Lymphoblastic predominance of blastic phase in children with chronic myeloid leukaemia treated with imatinib: A report from the I-CML-Ped Study. <i>European Journal of Cancer</i> , 2020, 137, 224-234.	2.8	9
74	Single dose (4.5 mg/m <sup>2</sup> ) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, 198, 373-381.	2.5	9
75	Screening of ETO2-GLIS2-induced Super Enhancers identifies targetable cooperative dependencies in acute megakaryoblastic leukemia. <i>Science Advances</i> , 2022, 8, eabg9455.	10.3	9
76	Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 1878-1882.	7.2	8
77	Effectiveness of brentuximab vedotin before and after allogeneic stem cell transplantation in the management of transformed mycosis fungoides. <i>British Journal of Dermatology</i> , 2020, 182, 1503-1504.	1.5	8
78	<i>KZF1</i> alterations predict poor prognosis in adult and pediatric T-ALL. <i>Blood</i> , 2021, 137, 1690-1694.	1.4	8
79	Germline pathogenic variants in transcription factors predisposing to pediatric acute myeloid leukemia: results from the French ELAM02 trial. <i>Haematologica</i> , 2021, 106, 908-912.	3.5	8
80	Allergies, genetic polymorphisms of Th2 interleukins, and childhood acute lymphoblastic leukemia: The ESTELLE study. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29402.	1.5	7
81	NUP98-NSD1 fusion by insertion in acute myeloblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2008, 180, 43-46.	1.0	6
82	Is Acute Myeloblastic Leukemia in Children Under 2 Years of Age a Specific Entity? A Report from the FRENCH ELAM02 Study Group. <i>HemaSphere</i> , 2019, 3, e316.	2.7	6
83	Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France. <i>British Journal of Haematology</i> , 2020, 188, 170-173.	2.5	6
84	End-of-life care in children and adolescents with cancer: perspectives from a French pediatric oncology care network. <i>Tumori</i> , 2021, , 030089162110133.	1.1	5
85	Toward Pediatric T Lymphoblastic Lymphoma Stratification Based on Minimal Disseminated Disease and NOTCH1/FBXW7 Status. <i>HemaSphere</i> , 2021, 5, e641.	2.7	5
86	Relevance of a One-Year Maintenance Therapy with Interleukin-2 in the Treatment of Childhood Acute Myeloid Leukemia: Results from the French Multicenter, Phase III, Randomized Controlled Sfce Trial, ELAM02. <i>Blood</i> , 2014, 124, 378-378.	1.4	5
87	Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29441.	1.5	5
88	Splenic infarction in a child revealing chronic myeloid leukemia. <i>European Journal of Pediatrics</i> , 2012, 171, 1141-1142.	2.7	4
89	Congenital Disseminated Extrarenal Malignant Rhabdoid Tumor. <i>Pediatric and Developmental Pathology</i> , 2015, 18, 401-404.	1.0	4
90	Impact of therapy in a cohort of unselected children with Down Syndrome-associated Acute Lymphoblastic Leukaemia. <i>British Journal of Haematology</i> , 2016, 174, 983-985.	2.5	4

#	ARTICLE	IF	CITATIONS
91	Naevoid acanthosis nigricans or RAVEN (rounded and velvety epidermal naevus) and mosaic <i>FGFR3</i> and <i>FGFR2</i> mutations. <i>British Journal of Dermatology</i> , 2019, 180, 955-957.	1.5	4
92	Malignant Ectomesenchymoma: A Potential Pitfall of Diagnosis in the Spectrum of Pediatric Small Blue Round Cell Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, e63-e64.	1.2	4
93	Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles. <i>Blood</i> , 2020, 136, 30-31.	1.4	4
94	Caution encouraged in next-generation sequencing immunogenetic analyses in acute lymphoblastic leukemia. <i>Blood</i> , 2020, 136, 1105-1107.	1.4	3
95	Ex vivo drug sensitivity profiling-guided treatment of a relapsed pediatric mixed-phenotype acute leukemia with venetoclax and azacitidine. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29678.	1.5	3
96	Bone Mineral Density Evolution and Its Determinants in Long-term Survivors of Childhood Acute Leukemia. <i>HemaSphere</i> , 2021, 5, e518.	2.7	2
97	<i>VPS4A</i> mutation in syndromic congenital hemolytic anemia without obvious signs of dyserythropoiesis. <i>American Journal of Hematology</i> , 2021, 96, E121-E123.	4.1	2
98	Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols. <i>Leukemia</i> , 2021, , .	7.2	2
99	Blaschko-linear lichen planus of the face: A retrospective study of 6 cases and a literature review. <i>Annales De Dermatologie Et De Venereologie</i> , 2022, 149, 112-118.	1.0	1
100	Imatinib Has a Negative Impact On Growth In Children With Previously Untreated Chronic Myeloid Leukaemia (CML) In Early Chronic Phase (CP): Results Of The French National Study. <i>Blood</i> , 2013, 122, 4001-4001.	1.4	1
101	Safety and Efficacy of Blinatumomab Used in Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Treated in French Hematological Centers. <i>Blood</i> , 2016, 128, 5190-5190.	1.4	1
102	Les unions de concertation pluridisciplinaire en onco-hématologie pédiatrique. <i>Archives De Pédiatrie</i> , 2012, 19, H129-H130.	1.0	0
103	Parcours de soins d'enfants en situation palliative suivis en hématologie-oncologie pédiatrique en Île-de-France. <i>Revue D'Oncologie Hématologie Pédiatrique</i> , 2016, 4, 106-112.	0.1	0
104	Excellent Prognosis of Late Relapses of ETV6/RUNX1 Childhood Acute Lymphoblastic Leukemia: Lessons From the FRALLE 93 Protocol. <i>Blood</i> , 2011, 118, 1508-1508.	1.4	0
105	Daunorubicin or Not During the Induction Treatment of Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): The Randomized Fralle 2000-A Protocol. <i>Blood</i> , 2012, 120, 135-135.	1.4	0
106	Modeling Growth Of Pediatric T-ALL In Vivo and In Vitro: Clinical Meaning and Activation Of The NFkB Pathway. <i>Blood</i> , 2013, 122, 2571-2571.	1.4	0
107	Genomic Landscape of Pediatric CBF-AML By SNP-Array Karyotyping and Extensive Mutational Analysis. <i>Blood</i> , 2014, 124, 1007-1007.	1.4	0
108	ETO2-GLIS2 Controls Differentiation Arrest and Self-Renewal through Aberrant Enhancers Regulation in Pediatric Leukemia. <i>Blood</i> , 2016, 128, 572-572.	1.4	0